Caladrius Biosciences Stock Price, News & Analysis (NASDAQ:CLBS)

$4.28 0.00 (0.00 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$4.28
Today's Range$4.04 - $4.31
52-Week Range$2.63 - $7.79
Volume2,565 shs
Average Volume33,793 shs
Market Capitalization$40.35 million
P/E Ratio2.03
Dividend YieldN/A
Beta1.7

About Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences logoCaladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLBS
CUSIPN/A
Phone908-842-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio5.78%
Quick Ratio5.78%

Price-To-Earnings

Trailing P/E Ratio2.02843601895735
Forward P/E Ratio-1.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.28 million
Price / Sales1.15
Cash FlowN/A
Price / CashN/A
Book Value$0.50 per share
Price / Book8.56

Profitability

Trailing EPS$2.11
Net Income$-32,650,000.00
Net MarginsN/A
Return on Equity-96.80%
Return on Assets-43.98%

Miscellaneous

Employees209
Outstanding Shares9,470,000

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) announced its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.41. View Caladrius Biosciences' Earnings History.

When will Caladrius Biosciences make its next earnings announcement?

Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Caladrius Biosciences.

Where is Caladrius Biosciences' stock going? Where will Caladrius Biosciences' stock price be in 2018?

1 analysts have issued twelve-month target prices for Caladrius Biosciences' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Caladrius Biosciences' stock price to reach $7.00 in the next year. View Analyst Ratings for Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:

  • David J. Mazzo Ph.D., Chief Executive Officer, Independent Director (Age 59)
  • Joseph Talamo, Chief Financial Officer, Senior Vice President (Age 47)
  • Douglas W. Losordo M.D., Chief Medical Officer (Age 58)
  • Gregory B. Brown M.D., Director (Age 64)
  • Richard J. Berman J.D., Independent Director (Age 74)
  • Drew Bernstein CPA., , Independent Director (Age 59)
  • Martyn D. Greenacre, Independent Director (Age 75)
  • Steven Mark Klosk, Independent Director (Age 60)

Who owns Caladrius Biosciences stock?

Caladrius Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Macquarie Group Ltd. (0.32%). View Institutional Ownership Trends for Caladrius Biosciences.

Who bought Caladrius Biosciences stock? Who is buying Caladrius Biosciences stock?

Caladrius Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd.. View Insider Buying and Selling for Caladrius Biosciences.

How do I buy Caladrius Biosciences stock?

Shares of Caladrius Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of Caladrius Biosciences stock can currently be purchased for approximately $4.28.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $40.35 million and generates $35.28 million in revenue each year. The biotechnology company earns $-32,650,000.00 in net income (profit) each year or $2.11 on an earnings per share basis. Caladrius Biosciences employs 209 workers across the globe.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 106 ALLEN ROAD FOURTH FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]


MarketBeat Community Rating for Caladrius Biosciences (CLBS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Caladrius Biosciences (NASDAQ:CLBS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$7.00$6.75
Price Target Upside: 72.41% upside72.41% upside123.64% upside73.08% upside

Caladrius Biosciences (NASDAQ:CLBS) Consensus Price Target History

Price Target History for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ:CLBS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018HC WainwrightSet Price TargetBuy$7.00LowView Rating Details
11/9/2016Chardan CapitalReiterated RatingBuy$6.50N/AView Rating Details
5/14/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
4/30/2016Rodman & RenshawUpgradeBuyN/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Caladrius Biosciences (NASDAQ:CLBS) Earnings History and Estimates Chart

Earnings by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ CLBS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018($0.78)N/AView Earnings Details
11/9/2017Q3 2017($0.79)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.96)($0.88)ViewN/AView Earnings Details
5/18/2017Q1 2017($0.72)($1.12)$9.50 million$7.92 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.80)($0.73)$6.30 million$10.18 millionViewN/AView Earnings Details
11/7/2016Q3($1.55)($1.09)$7.70 million$9.32 millionViewListenView Earnings Details
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.80)($2.10)$10.40 million$7.49 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.30)($0.21)$6.00 million$5.89 millionViewN/AView Earnings Details
8/6/2015Q215($0.32)($0.31)$5.20 million$5.87 millionViewN/AView Earnings Details
5/5/2015Q1 2015($4.60)($4.80)$4.50 million$3.17 millionViewN/AView Earnings Details
3/2/2015Q4 2014($4.90)($4.40)$5.20 million$5.28 millionViewN/AView Earnings Details
10/30/2014Q3 2014($0.41)($0.44)$4.00 million$4.12 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.28)($0.38)$4.70 million$4.49 millionViewN/AView Earnings Details
5/8/2014Q1 2014($3.30)$4.06 millionViewN/AView Earnings Details
3/13/2014Q4 2013($4.70)$4.08 millionViewN/AView Earnings Details
11/7/2013Q3 2013($4.50)$3.71 millionViewN/AView Earnings Details
8/8/2013Q2 2013($4.60)$4.36 millionViewN/AView Earnings Details
5/9/2013Q1 2013($5.00)($5.00)$4.20 million$2.52 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
8/14/2012Q2 2012($5.40)ViewN/AView Earnings Details
5/11/2012Q1 2012($6.80)ViewN/AView Earnings Details
3/20/2012Q4 2011($7.00)$1.20ViewN/AView Earnings Details
11/11/2011Q3 2011($12.00)($8.00)ViewN/AView Earnings Details
8/15/2011Q2 2011($9.00)($13.40)ViewN/AView Earnings Details
11/12/2010Q3 2010($10.00)($12.60)ViewN/AView Earnings Details
8/16/2010Q2 2010($7.00)($11.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Caladrius Biosciences (NASDAQ:CLBS) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.54 EPS
Next Year EPS Consensus Estimate: $-2.94 EPS

Dividends

Dividend History for Caladrius Biosciences (NASDAQ:CLBS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Caladrius Biosciences (NASDAQ CLBS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.10%
Institutional Ownership Percentage: 6.54%
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ CLBS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2017Eric WeiDirectorSell6,575$4.77$31,362.75View SEC Filing  
2/6/2017Eric WeiDirectorSell8,425$4.61$38,839.25View SEC Filing  
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Caladrius Biosciences (NASDAQ CLBS) News Headlines

Source:
DateHeadline
Caladrius Biosciences (CLBS) Presents At BIO CEO & Investor Conference - SlideshowCaladrius Biosciences (CLBS) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:28 PM
Caladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference - GlobeNewswire (press release)Caladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 8 at 7:01 AM
Caladrius Biosciences to Present at the 2018 BIO CEO & Investor ConferenceCaladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 7:01 AM
Caladrius Biosciences (CLBS) PT Set at $7.00 by HC WainwrightCaladrius Biosciences (CLBS) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - January 20 at 1:58 PM
Zacks Investment Research Lowers Caladrius Biosciences (CLBS) to SellZacks Investment Research Lowers Caladrius Biosciences (CLBS) to Sell
www.americanbankingnews.com - January 10 at 7:46 PM
Caladrius Biosciences (CLBS) & Its Competitors Head-To-Head ReviewCaladrius Biosciences (CLBS) & Its Competitors Head-To-Head Review
www.americanbankingnews.com - January 1 at 3:28 AM
Reviewing Caladrius Biosciences (CLBS) and Its PeersReviewing Caladrius Biosciences (CLBS) and Its Peers
www.americanbankingnews.com - December 26 at 11:54 PM
Caladrius Biosciences (CLBS) and Its Competitors Financial AnalysisCaladrius Biosciences (CLBS) and Its Competitors Financial Analysis
www.americanbankingnews.com - December 19 at 5:26 AM
Financial Analysis: Caladrius Biosciences (CLBS) vs. Its PeersFinancial Analysis: Caladrius Biosciences (CLBS) vs. Its Peers
www.americanbankingnews.com - December 17 at 3:12 AM
Contrasting Caladrius Biosciences (CLBS) and The CompetitionContrasting Caladrius Biosciences (CLBS) and The Competition
www.americanbankingnews.com - December 13 at 7:24 PM
Caladrius Biosciences (CLBS) versus Its Peers Head to Head ReviewCaladrius Biosciences (CLBS) versus Its Peers Head to Head Review
www.americanbankingnews.com - December 12 at 9:34 PM
ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 5:14 PM
Caladrius Biosciences (CLBS) vs. Its Competitors Financial ReviewCaladrius Biosciences (CLBS) vs. Its Competitors Financial Review
www.americanbankingnews.com - December 4 at 1:34 AM
Caladrius Biosciences to Present at the 10th Annual LD Micro Main Event - GlobeNewswire (press release)Caladrius Biosciences to Present at the 10th Annual LD Micro Main Event - GlobeNewswire (press release)
globenewswire.com - December 3 at 5:20 PM
Zacks Investment Research Lowers Caladrius Biosciences, Inc. (CLBS) to HoldZacks Investment Research Lowers Caladrius Biosciences, Inc. (CLBS) to Hold
www.americanbankingnews.com - November 16 at 5:34 PM
Caladrius Biosciences, Inc. (CLBS) Lifted to Buy at Zacks Investment ResearchCaladrius Biosciences, Inc. (CLBS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:00 PM
Caladrius Biosciences, Inc. (CLBS) Releases  Earnings Results, Beats Expectations By $0.41 EPSCaladrius Biosciences, Inc. (CLBS) Releases Earnings Results, Beats Expectations By $0.41 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
Caladrius Biosciences, Inc. (CLBS) Earns Buy Rating from HC WainwrightCaladrius Biosciences, Inc. (CLBS) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 10 at 10:24 AM
Caladrius Biosciences Reports 2017 Third Quarter Results - GlobeNewswire (press release)Caladrius Biosciences Reports 2017 Third Quarter Results - GlobeNewswire (press release)
www.globenewswire.com - November 10 at 9:52 AM
What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences, Inc. to Host Earnings CallCaladrius Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences Reports 2017 Third Quarter ResultsCaladrius Biosciences Reports 2017 Third Quarter Results
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences to Participate at Upcoming November Conferences - GlobeNewswire (press release)Caladrius Biosciences to Participate at Upcoming November Conferences - GlobeNewswire (press release)
globenewswire.com - November 2 at 6:08 PM
Caladrius Biosciences to Host 2017 Third Quarter Business Update Conference Call on November 9, 2017 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host 2017 Third Quarter Business Update Conference Call on November 9, 2017 at 4:30 p.m. Eastern Time
finance.yahoo.com - November 2 at 6:08 PM
Caladrius Biosciences to Participate at Upcoming November ConferencesCaladrius Biosciences to Participate at Upcoming November Conferences
finance.yahoo.com - November 1 at 6:02 PM
Caladrius Biosciences, Inc. (CLBS) Set to Announce Quarterly Earnings on MondayCaladrius Biosciences, Inc. (CLBS) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Caladrius Biosciences, Inc. (CLBS) Downgraded by Zacks Investment ResearchCaladrius Biosciences, Inc. (CLBS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 11 at 5:56 PM
Caladrius Biosciences (CLBS) and Global Blood Therapeutics (GBT) Head-To-Head ReviewCaladrius Biosciences (CLBS) and Global Blood Therapeutics (GBT) Head-To-Head Review
www.americanbankingnews.com - October 11 at 12:08 AM
Head-To-Head Survey: Caladrius Biosciences (CLBS) and Enanta Pharmaceuticals (ENTA)Head-To-Head Survey: Caladrius Biosciences (CLBS) and Enanta Pharmaceuticals (ENTA)
www.americanbankingnews.com - October 6 at 4:28 AM
How Long Will Loss-Making Caladrius Biosciences Inc (CLBS) Survive?How Long Will Loss-Making Caladrius Biosciences Inc (CLBS) Survive?
finance.yahoo.com - October 5 at 11:22 AM
Caladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMDCaladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD
www.streetinsider.com - October 4 at 12:08 PM
Caladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD - StreetInsider.comCaladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD - StreetInsider.com
www.streetinsider.com - October 2 at 10:26 PM
Caladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support Clinical Study of CLBS14 in Patients with Coronary Microvascular DysfunctionCaladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support Clinical Study of CLBS14 in Patients with Coronary Microvascular Dysfunction
finance.yahoo.com - October 2 at 5:25 PM
Caladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the MesaCaladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the Mesa
globenewswire.com - September 28 at 8:42 AM
Why These 4 Biotech Stocks May Not Lose Momentum Soon - NasdaqWhy These 4 Biotech Stocks May Not Lose Momentum Soon - Nasdaq
www.nasdaq.com - September 11 at 5:55 PM
Why These 4 Biotech Stocks May Not Lose Momentum SoonWhy These 4 Biotech Stocks May Not Lose Momentum Soon
finance.yahoo.com - September 11 at 5:55 PM
Type 1 Diabetes May Soon Meet Its MatchType 1 Diabetes May Soon Meet Its Match
finance.yahoo.com - September 8 at 5:40 PM
Caladrius Biosciences to Participate at Upcoming September Conferences - NasdaqCaladrius Biosciences to Participate at Upcoming September Conferences - Nasdaq
www.nasdaq.com - September 8 at 3:21 AM
Caladrius Biosciences to Participate at Upcoming September ConferencesCaladrius Biosciences to Participate at Upcoming September Conferences
finance.yahoo.com - September 7 at 5:19 PM
Caladrius Biosciences (CLBS) "Buy" Rating Reiterated at HC WainwrightCaladrius Biosciences' (CLBS) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 6 at 3:56 PM
Caladrius Biosciences (CLBS) Reports Enrollment of 70th Subject in Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 ... - StreetInsider.comCaladrius Biosciences (CLBS) Reports Enrollment of 70th Subject in Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 ... - StreetInsider.com
www.streetinsider.com - September 5 at 6:47 PM
Caladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 DiabetesCaladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - September 5 at 6:47 PM
Critical Analysis: Arbutus Biopharma Corp (ABUS) and Caladrius Biosciences (CLBS)Critical Analysis: Arbutus Biopharma Corp (ABUS) and Caladrius Biosciences (CLBS)
www.americanbankingnews.com - August 25 at 6:28 AM
Caladrius Biosciences, Inc. (CLBS) PT Set at $7.00 by HC WainwrightCaladrius Biosciences, Inc. (CLBS) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
Caladrius Biosciences, Inc. (CLBS) Posts  Earnings Results, Beats Estimates By $0.08 EPSCaladrius Biosciences, Inc. (CLBS) Posts Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - August 11 at 12:24 PM
Investor Network: Caladrius Biosciences, Inc. to Host Earnings CallInvestor Network: Caladrius Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - August 10 at 6:29 PM
Caladrius Biosciences Reports 2017 Second Quarter ResultsCaladrius Biosciences Reports 2017 Second Quarter Results
finance.yahoo.com - August 10 at 6:29 PM
Caladrius Biosciences to Host 2017 Second Quarter Results ... - GlobeNewswire (press release)Caladrius Biosciences to Host 2017 Second Quarter Results ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 11:50 PM
Caladrius Biosciences to Host 2017 Second Quarter Results Conference Call on August 10, 2017 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host 2017 Second Quarter Results Conference Call on August 10, 2017 at 4:30 p.m. Eastern Time
finance.yahoo.com - August 3 at 6:48 PM
Caladrius Biosciences, Inc. (CLBS) Set to Announce Earnings on MondayCaladrius Biosciences, Inc. (CLBS) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 31 at 8:15 AM

SEC Filings

Caladrius Biosciences (NASDAQ:CLBS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Caladrius Biosciences (NASDAQ:CLBS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Caladrius Biosciences (NASDAQ CLBS) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.